ImmuPharma narrows loss and targets P140 partnership in 2026
ImmuPharma (AIM:IMM) published full-year results showing a narrowed pre-tax loss alongside disclosure of a post-period fundraise, as the company positions itself for what management described as a pivotal phase. Chief executive Tim McCarthy said the group is focused on securing a commercial partnership for its lupus peptide P140 during 2026, while fast-tracking its glucagon emergency treatment Kapiglucagon over the following two years. Chairman Ketan Patel added weight to the strategic narrative as the company seeks to convert its pipeline into partnered programmes. The shares eased 1.33% to 4.44p on the day.
Physiomics wins new and follow-on contracts through to end of 2027
Physiomics (AIM:PYC) announced a series of new and follow-on contracts to deliver modelling, biometrics and data-science support across Phase 1-2 clinical programmes for both UK and international clients, with revenue now visible through to the end of 2027. Chief executive Dr Peter Sargent highlighted the breadth of the mandate, spanning multiple therapeutic areas and geographies, as evidence of growing demand for the company's quantitative pharmacology services. The contract news lifted the shares 8.46% to 0.705p.
ValiRx's Cytolytix secures European patent for nanoparticle cancer delivery
ValiRx (AIM:VAL) announced that its majority-owned subsidiary Cytolytix has been granted European Patent EP4225803B1, covering a nanoparticle delivery system designed to transport anti-cancer peptides to tumour sites. The company said the grant strengthens its intellectual property estate and improves its position in commercial negotiations with potential partners. ValiRx (AIM:VAL) shares added 2.56% to 0.2p on the news.
FDA extends camizestrant decision date for additional data review
AstraZeneca (LSE:AZN) disclosed that the US Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) decision date for its camizestrant combination filing, granting additional time to review supplementary analyses requested in connection with the SERENA-6-based new drug application. The extension is procedural rather than a reflection of safety or efficacy concerns, and the company said it continues to work constructively with the regulator. Board member Susan Galbraith is among those overseeing the regulatory process. AstraZeneca (LSE:AZN) shares were broadly flat, edging up 0.11% to 13,976p.
